Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.74 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 7/20 | 0.52 |
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665308 | 0.91 | MEN1 (0.67) | MAP2K1NUDT1MEN1KMT2ACLEC4M | |
| SCHEMBL367606 | 0.86 | MAP2K1 (0.62) | MAP2K1NUDT1MEN1KMT2AADORA2A | |
| SCHEMBL29526844 | 0.85 | MAP2K1 (1.00) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL1607007 | 0.85 | MAP2K1 (1.00) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL27709892 | 0.81 | MAP2K1 (0.76) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL12729266 | 0.81 | MAP2K1 (0.66) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL26047920 | 0.80 | MAP2K1 (0.74) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| Methoxymethane SCHEMBL28146835 | 0.79 | MAP2K1 (0.77) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL2991525 | 0.79 | MAP2K1 (0.71) | MAP2K1KMT2AADORA2AMTNR1ACNR2 | |
| SCHEMBL8513280 | 0.78 | MAP2K1 (0.62) | MAP2K1KMT2AADORA2AMTNR1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109223792-A | A kind of pharmaceutical composition and preparation method thereof for treating osteoarthritis | 李明霞 | 2019-01-18 | — | — | CN | claimed |
| CN-119080779-A | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112823005-B | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-109223792-A | A kind of pharmaceutical composition and preparation method thereof for treating osteoarthritis | 李明霞 | 2019-01-18 | — | — | CN | disclosed |
| US-8466170-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466170-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20110166175-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166175-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2010020308-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166175-A1 | 7-AZAINDOLE DERIVATIVES | JAK3, AZI2, MYLK2 | MAP2K1 789/4885NUDT1 3485/4885MEN1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.